DSS Licenses IntelliDose to Standardize VA Oncology Practices - PR Inside
- IntrinsiQ Company Contact: Ted Owens, 781-434-3331 ted.owens@intrinsiq.com or IntrinsiQ Media Contact: Lesley Cannata, 617-969-9192 lcannata@corporateink.com or DSS Company Contact: Mark Byers, 561-227-0207 mbyers@dssinc.com or DSS Media Contact

Milestone Bioscience to Market Access Pharma s Oncology-Related - Genetic Engineering News
Milestone Biosciences obtained marketing rights to Access Pharmaceuticals cancer-related drug in the U.S. and Canada in a deal worth about $10 million. MuGard is indicated for the management of oral mucositis, a side effect of anticancer

Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC - Forbes
DALLAS, Aug. 18 /PRNewswire-FirstCall/ — ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access

AMRI Initiates Phase I Study of Proprietary Oncology Drug Candidate - PR Inside
www.amriglobal.com - AMRI (NASDAQ: AMRI) today announced the initiation of its Phase I study of ALB109564(a), a novel tubulin inhibitor, which is designed to kill cancer cells by preventing cell mitosis. The study will be conducted at four clinical

Medco, FDA to study role of genetics in medicine - Reuters
NEW YORK, Aug 18 (Reuters) - Medco Health Solutions Inc (MHS.N: Quote , Profile , Research , Stock Buzz ) will collaborate with the U.S. Food and Drug Administration to research the role of genetics in the safety and effectiveness of drugs, the

Trubion Pharmaceuticals Announces Appointment of New Chief Medical - Forbes
SEATTLE, Aug. 18 /PRNewswire-FirstCall/ — Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Scott C. Stromatt, M.D., has been appointed Trubion's senior vice president and chief medical officer (CMO). Dr. Stromatt replaces Daniel J